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Abstract
Telomeres are involved in processes like cellular growth, chromosomal stability, and proper segregation to daughter
cells. Telomere length measured in leukocytes (LTL) has been investigated in different cancer types, including multiple
myeloma (MM). However, LTL measurement is prone to heterogeneity due to sample handling and study design
(retrospective vs. prospective). LTL is genetically determined; genome-wide association studies identified 11 SNPs that,
combined in a score, can be used as a genetic instrument to measure LTL and evaluate its association with MM risk.
This approach has been already successfully attempted in various cancer types but never in MM. We tested the
“teloscore” in 2407 MM patients and 1741 controls from the International Multiple Myeloma rESEarch (IMMeNSE)
consortium. We observed an increased risk for longer genetically determined telomere length (gdTL) (OR= 1.69; 95%
CI 1.36–2.11; P= 2.97 × 10−6 for highest vs. lowest quintile of the score). Furthermore, in a subset of 1376 MM patients
we tested the relationship between the teloscore and MM patients survival, observing a better prognosis for longer
gdTL compared with shorter gdTL (HR= 0.93; 95% CI 0.86–0.99; P= 0.049). In conclusion, we report convincing
evidence that longer gdTL is a risk marker for MM risk, and that it is potentially involved in increasing MM survival.
Introduction
Multiple myeloma (MM) is a plasma cell malignancy
that arises from a single clone of malignant plasma cells
(PCs) in the bone marrow. It has a worldwide incidence of
2.1/100,000 new cases every year, ranking as the second
most common hematological cancer1. MM has usually a
late onset with a mean age at diagnosis around 60 years1.
There are overwhelming evidences that genetic variability
influences the risk of developing MM2–8. In the recent years
the importance of genetics has also emerged in MM
response to treatment and survival9–15. Alongside poly-
morphic variants, another emerging marker of susceptibility
and prognosis for several diseases is telomere length. Telo-
meres are specialized structures that cap the end of chro-
mosomes and are involved in several processes like cellular
growth, chromosomal stability, and proper segregation to
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daughter cells16. Telomerases are the most important
enzymes involved in telomere replication and their dys-
function is considered a cancer hallmark17. Telomere length
measured in leukocytes (LTL) has been used to investigate
the susceptibility to different cancer types including several
hematological malignancies18–25, among which MM for
which only two studies of small size have been attempted, a
prospective cohort study and a retrospective case control
study21,26. In a meta-analysis conducted by Xu and collea-
gues the role of LTL in relation to survival in several cancer
types has been investigated27. However, MM was not among
the tumors investigated by the authors and the only study
conducted on MM survival consisted of five patients where
telomere length was measured in bone marrow cells, com-
paring malignant vs. non-malignant cells28.
Telomere length is highly correlated across tissues29,30, it is
reasonably stable during time, as assessed in a longitudinal
study18, and therefore it is considered a valid surrogate for
the measure of telomere length in specific tissues.
However, LTL measurement is prone to heterogeneity due
to sample handling (DNA extraction methods used, storage
of blood and/or DNA, elution buffer used)31. In addition,
the analysis of LTL is sensitive to other confounders, such as
the epidemiologic design of the study (retrospective vs.
prospective) and, in studies on cancer, whether the subjects
have received chemotherapy or not. LTL is genetically
determined (gdTL) with an estimated heritability that ranges
from 0.44 to 0.7032,33. Recently genome-wide association
studies (GWAS) have identified 11 SNPs23,34–36 that, col-
lectively, explain 2.28% of LTL variability and can be used as
a genetic instrument in a Mendelian randomization fashion.
This approach has been already successfully tested in rela-
tion to the risk of developing various cancer types23,37–45,
but was never done in MM. We have tested the genetic
score (henceforth called “teloscore”) in the context of the
International Multiple Myeloma rESEarch (IMMeNSE)
consortium to investigate the relationship between gdTL
and MM risk and survival.
Materials and methods
Study population
This study was conducted within the IMMeNSE con-
sortium, that has been extensively described elsewhere46.
We used DNA samples from 2407 MM patients and 1741
controls for whom information on sex, age (age at diag-
nosis for the cases/age at recruitment for the controls),
and country of origin (Denmark, France, Hungary, Israel,
Italy, Poland, Portugal, and Spain) was collected. Cases
were defined by a confirmed diagnosis of MM according
to the International Myeloma Working Group (IMWG)
criteria47. In addition, clinical data such as disease stage
according to Durie-Salmon (DS) staging system48 and/or
International Staging System (ISS)49, first-line treatment
received, based on bortezomib/immunomodulatory drugs
(defined as “new treatments”) or any other regimen, such
as vincristine/adriamycin/dexamethasone or melphalan/
prednisone (defined as “old treatments”) and overall sur-
vival (OS) were retrospectively collected from medical
records. Information about DS stage was available for
1235 cases, while the stage according to ISS was available
for 1022 cases, and for 984 cases information on both
systems was available. Controls were selected among the
general population as well as among hospitalized subjects
or among blood donors in the same geographic areas
where the cases were collected. Characteristics of the
study population are summarized in Table 1. The
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IMMEnSE study protocol was approved by the Ethics
Committee of the Medical Faculty of the University of
Heidelberg (reference number: S-004/2020). Following
the guidelines of the Declaration of Helsinki, written
informed consent was obtained from each participant.
SNP selection
To build the teloscore we used 11 single nucleotide poly-
morphisms (SNPs) (ZNF676-rs412658, TERT-rs2736100,
CTC1-rs3027234, DHX35-rs6028466, PXK-rs6772228,
NAF1-rs7675998, ZNF208-rs8105767, OBFC1-rs9420907,
ACYP2-rs11125529, TERC-rs10936599, and ZBTB46-
rs755017), identified through GWAS, that affect telomere
length23,34–36. Characteristics of the SNPs under investiga-
tion are summarized in Supplementary Table 1.
Genotyping
DNA samples were extracted from whole blood. Gen-
otyping was conducted in 384-well plates, using TaqMan
(ABI, Applied Biosystems, Foster City, CA, USA) tech-
nology according to the manufacturer’s recommenda-
tions. For quality control purposes around 10% of the
samples were duplicated in order to check the con-
cordance between the genotypes. Case/control status was
unknown to the person performing the genotyping.
Fluorescent signals of the genotyping assays were read on
PCR plates by a spectrophotometer (Ω, BMG LABTECH,
Ortenberg, Germany) and the software KlusterCaller
(LGC Group, Teddington, UK) was used to determine
genotypes.
Teloscore computation
The “teloscore” was computed as follows: for each SNP
the number of alleles associated with longer telomeres
(according to the results of the literature) was counted
and added up for each study subject, resulting in the
unweighted score. Therefore, considering 11 SNPs, the
unweighted score could assume any value between 0
(shortest telomeres) and 22 (longest telomeres). We then
created a weighted score for each study subject. First, we
took from the literature estimates of the per-allele effect
on LTL in base pairs for each SNP (Supplementary Table
1). Then, we multiplied for each SNP the number of
alleles associated with longer telomeres by the per-allele
effect on LTL in base pairs that were then summed up for
each study subject. The weighted score thus represents
the estimated difference in telomere length, measured in
base pairs, attributable to the SNPs under investigation.
The concordance between the teloscore built with SNPs
and the relative telomere length measured with real time
quantitative PCR was described in detail elsewhere37.
Only a subset of the study subjects had a 100% SNP call
rate (1769 cases and 1207 controls). For survival analyses,
unweighted and weighted teloscores were built with all
the individuals with complete data on stage, therapy
received and OS. The number of cases with 100% SNP call
rate was 1000 with DS staging system information and
813 with ISS.
In order to be able to compute comparable score values
for all study subjects, we also considered average values
for each score. Supplementary Table 2 shows examples of
how the teloscores were generated.
Statistical analysis
The association between the individual SNPs and MM
risk was tested using unconditional logistic regression
computing odds ratios (ORs) and 95% confidence inter-
vals (CIs). We used an allelic (log-additive) and a codo-
minant model of inheritance. The threshold for statistical
significance was therefore p= 0.05/(11 SNPs x 2 models)
= 0.05/22= 0.0023.
For both teloscores (weighted and unweighted) we
calculated quintiles based on the distribution of values in
the controls. The association between the teloscores and
MM risk was tested with logistic regression computing
OR and 95% CIs.
All analyses were adjusted for age, sex, and country of
origin.
Survival analysis to assess the effect of the SNPs and
the teloscore on OS of MM patients was done using
Cox regression, calculating hazard ratio (HR), and 95%
CI. OS was defined as the time between MM diagnosis
and last follow up for alive patient or death. Survival
analyses were carried out with individual SNPs and with
both teloscores (weighted and unweighted). We built
the teloscores calculating quintiles based on the dis-
tribution of values in all the individuals with staging,
therapies and OS data. The analyses were adjusted for
age, sex, country of origin, MM stage (according to DS
or ISS), and first-line therapy.
To better assess the causality of the association
between LTL and MM onset and progression we used a
Mendelian randomization approach considering the 11
SNPs as genetic instruments of the exposure, and risk
of developing MM and MM OS as outcomes of interest.
We utilized the inverse variance weighted (IVW)
regression because on the premise of absence of
directional pleiotropy, it provides consistently robust
causal effect estimates50,51. The Egger (MR-Egger)
estimation method was used to test for possible pleio-
tropic effects of the genetic instruments50,51. Finally to
assess evidence of heterogeneity between the poly-
morphisms, the Cochran Q′ heterogeneity and Bowden
I2GX statistics were computed to obtain an estimate of
instrument strength for the MR-Egger analysis52.
Additional information has been given elsewhere50,51.
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Analyses were carried out with the Mendelian rando-
mization package in R V0.5.0 (30 Sept. 2020).
Bioinformatic tools
Several bioinformatic tools were used in order to
identify functional relevance for the polymorphic variants
showing the most promising associations with risk of
developing MM. In particular, RegulomeDB (https://
www.regulomedb.org/regulome-search/)53 was used to
identify the regulatory potential of the region nearby each
SNP while the GTEx portal web site (https://www.
gtexportal.org) was used to identify potential associa-
tions between the SNP and expression levels of nearby
genes (eQTL)54.
Results
Characteristics of the study population are summarized
in Table 1. The SNPs under investigation are summarized
in Supplementary Table 1. All the selected SNPs were in
Hardy–Weinberg Equilibrium (HWE) in the control
population. The average call rate of the SNPs used for
statistical analysis was 96.3%. Concordance with dupli-
cated samples was higher than 99%.
We observed several associations between individual SNPs
and MM risk. In particular, two polymorphisms showed a
statistically significant association considering the
Bonferroni-corrected threshold (p < 0.0023). TERC-
rs10936599-T was associated with decreased risk of devel-
oping MM (ORhomozygous= 0.55; 95% CI 0.39–0.76; P=
2.87 × 10−4), while OBFC1-rs9420907-C was associated with
increased MM risk (ORheterozygous= 1.32; 95%CI 1.12–1.55;
P= 7.78 × 10−4). All the results of the risk analysis con-
sidering the SNPs individually are shown in Table 2.
Association of the “teloscore” with MM risk
Supplementary Table 2 illustrates how the teloscores
were generated. We tested the association between the
unweighted and weighted teloscore with MM risk in
individuals that had 100% call rate only (1769 cases and
1207 controls). We observed an increased risk for indivi-
duals that had longer gdTL. The association was similar in
terms of estimates and P values when comparing indivi-
duals belonging to the highest quintile with individuals
belonging to the lowest quintile, for the unweighted (OR=
1.36; 95% CI 1.07–1.73; P= 0.013) and weighted (OR=
1.39; 95% CI 1.08–1.80; P= 0.011) scores (Table 3).
We performed an additional analysis using all the
individuals and the average scores rather than the abso-
lute values (see Methods). We observed a strong asso-
ciation between long gdTL and increased risk of MM
when analyzing the score as a categorical variable with a
stronger association observed with the weighted score
(OR= 1.69; 95% CI 1.36–2.11; P= 2.97 × 10−6 for highest
vs. lowest quintile) compared to the unweighted score
(OR= 1.58; 95% CI 1.28–1.94; P= 1.93 × 10−5) (Table 3).
Considering that TERC-rs10936599 is a well-known risk
locus for MM, we have also computed a score considering
all the SNPs with the exception of this one, observing
results that are in line with what we observed with the 11
SNP score (Supplementary Table 3).
We also estimated the correlation between MM risk and
the genetic score using a Mendelian randomization
Table 2 Association between single SNPs and MM risk.
SNP Gene Allele MAFa EAa Allelic modelb Codominant modelc
M/m HR1 95% CI1 Pvalue HRHet 95% CI Pvalue HRHom 95% CI Pvalue
rs11125529 ACYP2 C/A 0.11 A 0.99 0.86–1.16 0.994 1.10 0.92–1.31 0.299 0.63 0.37–1.07 0.093
rs6772228 PXK T/A 0.04 T 0.81 0.62–1.07 0.121 0.75 0.50–0.99 0.048 1.91 0.43–8.32 0.389
rs10936599 TERC C/T 0.24 C 0.79 0.70–0.90 1.72 × 10−4 0.84 0.72–0.98 0.027 0.55 0.39–0.76 2.87 × 10−4
rs7675998 NAF1 G/A 0.24 G 0.94 0.83–1.06 0.321 0.84 0.73–0.98 0.029 1.15 0.82–1.60 0.402
rs2736100 TERT A/C 0.5 C 1.07 0.96–1.18 0.223 1.07 0.89–1.28 0.479 1.14 0.92–1.39 0.223
rs9420907 OBFC1 A/C 0.13 C 1.17 1.03–1.35 0.020 1.32 1.12–1.55 7.78 × 10−4 0.88 0.57–1.35 0.556
rs3027234 CTC1 C/T 0.22 C 0.89 0.79–1.00 0.054 0.97 0.83–1.13 0.669 0.65 0.47–0.90 0.009
rs8105767 ZNF208 A/G 0.28 G 1.14 1.02–1.27 0.022 1.05 0.90–1.21 0.559 1.46 1.12–1.90 0.005
rs412658 ZNF676 C/T 0.35 T 1.01 0.91–1.12 0.866 1.02 0.88–1.18 0.826 1.01 0.81–1.27 0.920
rs6028466 DHX35 G/A 0.07 A 1.23 1.08–1.50 0.042 1.25 1.00–1.55 0.048 1.33 0.55–3.15 0.505
rs755017 ZBTB46 A/G 0.12 G 1.10 0.93–1.29 0.235 1.05 0.88–1.25 0.609 1.61 0.88–2.93 0.120
aMAF minor allele frequency, EA effect allele, allele associated with longer telomere length, OR odds ratio, 95% CI 95% coefficient interval.
bAllelic model: M vs. m, common allele vs. rare allele.
cCodominant model: Mm vs. MM, heterozygous carriers vs. common homozygous, mm vs. MM, rare homozygous vs. common homozygous.
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approach as previously described. The IVW regression
showed a highly significant association between the 11 SNPs
used as genetic instruments of exposure and risk of devel-
oping MM (coeff= 1.175, 95% CI 0.61–1.75, P= 5.38 ×
10−5), whereas the MR-Egger regression showed a statisti-
cally non-significant association (coeff= 0.532, 95% CI
−1.16 to 2.22, P= 0.538), although in line with IVW
regression, with the intercept slightly, but not significantly,
different from zero (intercept= 0.06, 95% CI −0.09 to 0.20,
P= 0.428). The Q′ heterogeneity statistic did not show
statistically significant heterogeneity between the poly-
morphisms (P= 0.111), and Bowden I2GX statistic showed
that the selected genetic variants have high power to detect
directional pleiotropy and causal effect for MR-Egger (I2=
93.1%). Scatter plots and forest plot of the causal estimate
for risk of developing MM are shown in Supplementary
Figs. 1 and 2, respectively.
Association between individual SNPs and teloscore with
MM OS
Survival analysis did not show any statistically sig-
nificant associations if considering multiple testing.
However, we found an association between TERC-
rs10936599-T allele carriers and worse MM survival
compared to C allele carriers (HRallelic= 1.20; 95% CI
1.00–1.43; P= 0.048) and an association between A allele
homozygous of the PXK-rs6772228 SNP and worse sur-
vival compared to homozygous for the common T allele
(HRhomozygous= 4.51; 95% CI 1.06–19.17; P= 0.041)
(Table 4 and Supplementary Table 4).
The analyses between teloscore and OS of MM patients
showed a trend between having longer gdTL and better
MM survival, considering the quintile as a continuous
variable for unweighted (HR= 0.93; 95%CI 0.85–0.99;
P= 0.046) or weighted (HR= 0.93; 95% CI 0.86–0.99;
Table 3 Association between teloscore and MM risk.
Type of score Quintiles Controls Cases Total OR 95% CI Pvalue
Unweighted, subjects with 100% call rate 1 342 438 780 1.00 — Ref.
2 250 344 594 1.03 0.81–1.31 0.788
3 226 327 553 1.18 0.93–1.51 0.178
4 180 293 473 1.32 1.02–1.71 0.032
5 209 367 576 1.36 1.07–1.73 0.013
Continuousa 1207 1769 2976 1.09 1.03–1.15 2.53 × 10−3
Unweighted scaled, all subjects 1 478 522 1000 1.00 — Ref.
2 356 449 805 1.09 0.88–1.34 0.422
3 338 448 786 1.25 1.01–1.55 0.037
4 252 440 692 1.59 1.28–1.99 4.17 × 10−5
5 317 548 865 1.58 1.28–1.94 1.93 × 10−5
Continuousa 1741 2407 4148 1.14 1.08–1.19 1.89 × 10−7
Weighted, subjects with 100% call rate 1 244 293 537 1.00 — Ref.
2 248 315 563 1.02 0.78–1.32 0.905
3 234 363 597 1.26 0.96–1.63 0.085
4 241 387 628 1.35 1.04–1.75 0.022
5 240 411 651 1.39 1.08–1.80 0.011
Continuousa 1207 1769 2976 1.10 1.04–1.16 1.20 × 10−3
Weighted scaled, all subjects 1 356 361 717 1.00 — Ref.
2 342 386 728 1.01 0.79–1.27 0.940
3 348 493 841 1.29 1.03–1.62 0.026
4 348 546 894 1.49 1.19–1.86 4.80 × 10−4
5 347 621 968 1.69 1.36–2.11 2.97 × 10−6
Continuousa 1741 2407 4148 1.15 1.09–1.21 1.07 × 10−8
aThe estimate measures the increase in risk associated with each increase of one quintile.
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P= 0.049) score, adjusted by DS staging system. Similar
results were obtained in the analyses adjusted by ISS
(Table 5).
The results of the Mendelian randomization analysis
performed with IVW regression and MR-Egger regression
showed an inverse, non-significant association between
MM survival and the genetic score built with the 11 SNPs
(coeff=−0.44, 95% CI −1.18 to 0.29, P= 0.238), with the
intercept of the MR-Egger regression non-significantly
different from zero (coeff=−0.108, 95% CI −0.28 to 0.07,
P= 0.227). Q′ heterogeneity (P= 0.391) did not show
statistically significant heterogeneity between the poly-
morphisms, and Bowden I2GX statistic did not show weak
instrument bias (92.8%). Scatter plots and forest plot of
the causal estimate for risk of developing MM are shown
in Supplementary Figs. 3 and 4, respectively.
In silico identification of functional effects
We tested the possible functional relevance of CTC1-
rs3027234, ZNF208-rs8105767, OBFC1-rs9420907, TERC
-rs10936599, and PXK-rs6772228, that were significant in
at least one analysis and the variants in linkage dis-
equilibrium (LD) with them using RegulomeDB
and GTEx.
RegulomeDB showed a value of 1b for CTC1-rs3027234
that indicates the presence of an eQTL, of at least one
transcription factor binding site and the region to be
sensitive to the action of DNase. Analyzing rs3027234 in
the GTEx portal, a correlation between the T allele and
lower gene expression was observed in 20 tissues
including whole blood, where it showed a strongly
significant association (P= 1.2 × 10−33). RegulomeDB
assigned to ZNF208-rs8105767 a value of 1 f, which
indicates a functional role similar to CTC1-rs3027234.
GTEx reported six associations with different genes for
rs8105767, and the strongest correlation was between the
A allele and lower expression of the ZNF257 gene (P=
1.6 × 10−25) in whole blood. RegulomeDB assigned to
OBFC1-rs9420907 and TERC-rs10936599 a value of 3a,
indicating the presence of at least one transcription factor
binding site and the region to be sensitive to the action of
DNase, and GTEx did not show any eQTL. RegulomeDB
assigned to PXK-rs6772228 a value of 7, indicating the
absence of a functional role. Despite that, rs6772228 is in
LD with rs77480019 (r2= 0.92) and rs73077957 (r2=
0.84) for which RegulomeDB assigned a value of 3a, but
GTEx did not show any eQTL in whole blood.
Discussion
Telomere length is considered a risk factor, or a risk
marker, for a large number of diseases including several
cancer types18–25. However, in spite of the number of
studies, including several with considerable sample size, it
is still unclear whether long or short telomeres are
responsible for the increase in risk. In addition to true
biological differences in various diseases, a possible
explanation for this uncertainty may be explained by the
technical heterogeneity due to sample handling and study
design used across the studies. For MM only two relatively
small studies have been attempted, one in a retrospective
case–control setting55 and the other in a prospective
cohort26, both reporting an association between longer
Table 4 Association between individual SNPs and MM OS, adjusted by stage (Durie-Salmon).
SNP Gene Allele MAFa EAa Allelic modelb Codominant modelc
M/m HRa 95% CIa Pvalue HRHet 95% CI Pvalue HRHom 95% CI Pvalue
rs11125529 ACYP2 C/A 0.11 A 0.90 0.71–1.13 0.369 0.89 0.68–1.16 0.391 0.59 0.37–1.93 0.710
rs6772228 PXK T/A 0.04 T 1.30 0.89–1.89 0.165 1.18 0.78–1.75 0.426 4.51 1.06–19.17 0.041
rs10936599 TERC C/T 0.24 C 1.20 1.00–1.43 0.048 1.23 0.98–1.54 0.066 1.34 0.80– 2.23 0.265
rs7675998 NAF1 G/A 0.24 G 1.18 0.98–1.42 0.080 1.11 0.88–1.40 0.374 1.62 0.99–2.63 0.053
rs2736100 TERT A/C 0.50 C 1.05 0.89–1.22 0.536 1.02 0.77–1.34 0.879 1.10 0.70–1.49 0.545
rs9420907 OBFC1 A/C 0.13 C 0.96 0.78–1.17 0.724 0.95 0.75–1.20 0.690 0.95 0.51–1.85 0.941
rs3027234 CTC1 C/T 0.22 C 1.03 0.86–1.23 0.726 1.00 0.79–1.25 0.993 1.15 0.71–1.83 0.559
rs8105767 ZNF208 A/G 0.28 G 1.01 0.85–1.19 0.913 1.06 0.84–1.32 0.612 0.95 0.62–1.42 0.799
rs412658 ZNF676 C/T 0.35 T 0.98 0.83–1.15 0.847 1.01 0.80–0.25 0.943 0.95 0.66–1.35 0.763
rs6028466 DHX35 G/A 0.07 A 1.15 0.86–1.52 0.350 1.10 0.78–1.54 0.562 1.58 0.58–4.27 0.369
rs755017 ZBTB46 A/G 0.12 G 0.86 0.67–1.09 0.216 0.92 0.70–1.20 0.559 0.44 0.14–1.37 0.158
aMAF minor allele frequency, EA effect allele, allele associated with longer telomere length, HR hazard ratio, 95% CI 95% coefficient interval.
bAllelic model: M vs. m, common allele vs. rare allele.
cCodominant model: Mm vs. MM, heterozygous carriers vs. common homozygous; mm vs. MM, rare homozygous vs. common homozygous.
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telomeres and increased risk of developing the disease.
Telomere length is at least in part genetically determined
and there are several studies that have successfully used
SNPs as genetic surrogates for telomere length to infer
risk of developing several tumor types23,37–45. This
approach has never been attempted in MM. LTL has been
tested in relation to cancer survival27, but never in MM
and the only study conducted in MM is very small (n= 5)
and used purified bone marrow cells and not whole
blood28.
Considering that LTL measure could be influenced by
several epidemiologic confounders or methodological
issues, the main advantage of the strategy used in this
study is that the exposure (the genotypes) is not influ-
enced by study design (prospective vs. retrospective), by
sample manipulation or by environmental variables since
genotypes are invariable throughout life. The aim of this
study was to test whether GWAS-identified SNPs
involved in telomere length, combined in a score, were
associated with MM risk and, for the first time, OS of MM
patients. Considering that individually each of the SNPs
explains a small proportion of LTL variability, we have
combined them in a score and performed a MR analysis to
better characterize the relation between gdTL and the
disease risk and survival.
We found a novel association between carriers of the C
allele OBFC1-rs9420907 SNP and increased MM risk (P=
7.78 × 10−4). The C allele of the SNP is also associated
with longer telomeres34,38. This gene product is associated
to the shelterin complex and is also a subunit of alpha
accessory factor (AAF) that is involved in the initiation of
DNA replication. We observed an increase in risk
Table 5 Association between teloscore and MM OS.
Type of score Quintiles OS adjusted by stage (DS) OS adjusted by stage (ISS)
Alive Deceased Total HR 95% CI Pvalue Alive Deceased Total HR 95% CI Pvalue
Unweighted, subjects with
100% call rate
1 158 65 223 1.00 — Ref. 130 45 175 1.00 — Ref.
2 142 52 194 1.11 0.77–1.60 0.564 115 41 156 1.21 0.78–1.85 0.382
3 134 48 182 0.98 0.67–1.43 0.930 120 36 156 0.92 0.59–1.43 0.726
4 117 42 159 0.72 0.48–1.07 0.106 164 50 214 0.77 0.51–1.15 0.210
5 133 43 176 0.84 0.57–1.24 0.393 54 17 71 0.89 0.50–1.56 0.685
Continuousa 684 250 934 0.93 0.85–1.01 0.103 583 189 772 0.92 0.82–1.02 0.138
Unweighted scaled, all
subjects
1 182 92 274 1.00 — Ref. 152 71 223 1.00 — Ref.
2 174 77 251 1.06 0.78–1.44 0.684 139 56 195 1.07 0.74–1.52 0.716
3 172 65 237 0.90 0.65–1.24 0.538 154 50 204 0.83 0.57–1.19 0.317
4 233 94 327 0.84 0.63–1.12 0.251 196 69 265 0.77 0.55–1.08 0.136
5 109 37 146 0.73 0.49–1.06 0.106 102 33 135 0.73 0.48–1.12 0.154
Continuousa 870 365 1235 0.93 0.85–0.99 0.046 743 279 1022 0.91 0.83–0.99 0.037
Weighted, subjects with
100% call rate
1 136 54 190 1.00 — Ref. 119 37 156 1.00 — Ref.
2 141 54 195 1.06 0.72–1.54 0.765 111 48 159 1.27 0.82–1.96 0.268
3 127 49 176 1.02 0.69–1.50 0.917 116 36 152 0.94 0.59–1.49 0.797
4 144 44 188 0.72 0.48–1.07 0.108 121 30 151 0.66 0.40–1.07 0.094
5 136 49 185 0.91 0.61–1.34 0.626 116 38 154 1.01 0.64–1.60 0.933
Continuousa 684 250 934 0.94 0.86–1.03 0.198 583 189 772 0.94 0.84–1.04 0.225
Weighted scaled, all
subjects
1 168 83 251 1.00 — Ref. 147 64 211 1.00 — Ref.
2 167 78 245 1.06 0.77–1.44 0.722 138 66 204 1.06 0.75–1.50 0.726
3 173 73 246 0.97 0.70–1.32 0.837 148 51 199 0.86 0.59–1.24 0.426
4 181 66 247 0.76 0.55–1.05 0.107 158 46 204 0.67 0.45–0.98 0.042
5 181 65 246 0.81 0.58–1.12 0.210 152 52 204 0.82 0.57–1.19 0.310
Continuousa 870 365 1235 0.93 0.86–0.99 0.049 743 279 1022 0.92 0.84–0.99 0.046
aThe estimate measures the increase in risk associated with each increase of one quintile.
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associated with the C allele of the rs3027234 polymorph-
isms and with G allele of the rs8105767. The CTC1-
rs3027234-C allele is associated with longer telomeres and,
according to GTEx, with an increased expression of the
gene in blood with a very high statistical significance (p=
1.2 × 10−33). It is therefore plausible that the C allele
contributes to an increase efficiency of the complex that in
turn results in longer telomeres that increase the risk of
developing MM. The G allele of rs8105767 is associated
with longer telomeres34 and, according to GTEX, it has an
effect on the expression of various genes in whole blood,
mainly ZNF257 (P= 1.6 × 10−25).
The main finding of this manuscript is the observation
that gdTL is associated with increased risk of MM. This
association is consistent in all the models we tested and
when using all the subjects it reached a very high statistical
significance, especially comparing individuals with the
longest telomeres with individuals with the shortest telo-
meres (quintile 5 vs. quintile 1; P= 2.97 × 10−6) or when
considering the quintile variable as continuous (P= 1.07 ×
10−8). This finding is in agreement with what was found in
the two studies that reported longer telomeres measured by
real-time PCR to be associated with increased risk of
developing the disease26,55 and it is also in line with a very
large study performed on a substantial number of different
cancer types, where the general trend for most cancers was
an association between longer genetically determined telo-
meres and increased risk23. To analyze in depth the asso-
ciation between gdTL and risk of MM, the 11 SNPs selected
were analyzed with a Mendelian randomization approach to
test the presence of directional pleiotropy and its influence
in the estimate of the causal effect between LTL and risk of
developing MM. The results were in line with the finding
obtained through teloscore analysis, supporting the evi-
dence for a causal effect of longer gdTL with an increased
MM risk. Moreover, the MR-Egger intercept was not sta-
tistically different from zero and the results of the hetero-
geneity tests were not statistically significant. These
observations suggest the absence of directional pleiotropy
and heterogeneity between the polymorphisms selected.
From a biologic point of view, longer telomeres (parti-
cularly as measured by the SNP teloscore, which repre-
sents the innate tendency to have longer or shorter
telomeres) could represent a marker of a cell that has a
higher dividing potential and therefore an increased ten-
dency in acquiring new potential harmful mutations23.
A potential limitation is that most of the controls used
in this study, as for almost all case–control studies, are
either blood donors or hospitalized individuals with
pathologies unrelated to MM. Considering that gdLTL
has been associated with several human traits, this may
represent a confounding factor of the analysis.
A point of novelty is represented by two borderline
associations between the allele associated with shorter TL
and a worse OS of MM patients, compared to the allele
associated with longer TL, both for TERC-rs10936599
(P= 0.048) and PXK-6772228 (P= 0.041). Furthermore,
the teloscore survival analyses showed that longer gdTL is
correlated with better MM patients OS compared to
patients with shorter gdTL. Despite this, the different
direction obtained for IVW and MR-Egger analyses did
not support a significant association of the teloscore with
OS of MM patients, although the Cochran’s Q statistic did
not show evidence of heterogeneity between the poly-
morphisms. A possible explanation for Mendelian ran-
domization results is that the increase of patient’s survival
could be due to pleiotropic effects of the genetic variants
that act on the outcome via a confounder.
Xu and colleagues conducted a thorough meta-analysis
to test the effect of LTL in cancer progression and survival
and even though MM was not included, their findings are
in agreement with ours i.e., shorter telomere associated
with worse prognosis27.
We do not have data for myeloma-specific mortality.
On the other hand, although in the last years many
advances in therapy have been made, MM remains an
incurable disease and therefore we presume that the vast
majority of deaths are disease specific.
It is worth noting that gdTL as measured in our work,
being based on germline polymorphisms that do not
change throughout life, is unaffected not only by age, but
also by any other biological mechanism induced by
environmental exposures (e.g., smoking) or therapeutic
exposures (e.g., anticancer treatments) that are known to
affect telomere length.
In conclusion, we present here convincing evidence that
longer gdTL is a risk marker for MM development.
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